Thetis Pharmaceuticals

Thetis is developing new medicines derived from a class of potent, naturally-occurring signaling molecules called Resolvins that promote immune homeostasis. Our lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug that offers a novel approach to engage BLT1, a key receptor that regulates important aspects of innate and adaptive immunity. Our disease targets - inflammatory bowel disease (IBD) and solid tumor cancers - represent high unmet medical needs.